Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 6/2008

01-06-2008 | Short Communication

Measurement of self-advocacy in cancer patients and survivors

Author: Carol J. Hermansen-Kobulnicky

Published in: Supportive Care in Cancer | Issue 6/2008

Login to get access

Abstract

Background

The Patient Self-Advocacy Scale, originally developed for use in HIV/AIDS patients, was adapted for use in cancer patients and survivors. The scale contains three dimensions: increased illness education, increased assertiveness with a doctor, and potential for mindful non-adherence.

Discussion and conclusion

Evidence for modest reliability and construct validity was found; however, ceiling effects exist for the Illness Education subscale, which supports the need to move beyond items regarding information seeking to perhaps include use and management of information.
Literature
1.
Brashers DE, Haas SM, Neidig JL (1996) The Patient Self-Advocacy Scale: measuring patient involvement in health care decision-making interactions. Health Comm 11(2):97–121CrossRef
2.
Chewning B, Hermansen Kobulnicky CJ (2007) Concordance and communication in cancer management. In: O’Hair HD, Kreps GL, Sparks L (eds) The handbook of communication and cancer care. Hampton, Cresskill, NJ, pp 343–363
3.
Clark E, Stovall E (1996) Advocacy: the cornerstone of cancer survivorship. Cancer Prac 5:239–244
4.
Degner LF, Sloan JA (1992) Decision making during serious illness: what role do patients really want to play? J Clin Epidem 45:941–950CrossRef
5.
Degner LF, Kristjanson L, Bowman D, Sloan J, O’Neil J et al (1997) Decisional preferences and informational needs in women with breast cancer. JAMA 277:1485–1492PubMedCrossRef
6.
Gattellari M, Butow PN, Tattersall MHN (2001) Sharing decisions in cancer care. Soc Sci Med 52:1865–1878PubMedCrossRef
7.
Gray RE, Doan BD, Church K (1991) Empowerment issues in cancer. Health Values 15(4):22–28
8.
9.
Krupat E, Irish JT (2007) Cancer patients as active participants in their care. In: O’Hair HD, Kreps GL, Sparks L (eds) The handbook of communication and cancer care. Hampton, Cresskill, NJ, pp 325–342
10.
11.
Maliski SL, Clerkin B, Litwin MS (2004) Describing a nurse case manager intervention to empower low-income men with prostate cancer. Onc Nurs Forum 31(1):57–64CrossRef
12.
Nunnally JC, Bernstein IH (1994) The assessment of reliability. In: Psychometric theory, 3rd edn. McGraw-Hill, Inc., New York, pp 248–292
13.
Rothenbacher D, Lutz MP, Porzsolt F (1997) Treatment decisions in palliative cancer care: patients’ preferences for involvement and doctors’ knowledge about it. Eur J Cancer 33:1184–1189PubMedCrossRef
14.
Skalla KA, Bakitas M, Furstenberg CT, Ahles T, Henderson JV (2004) Patients’ need for information about cancer therapy. Oncol Nurs Forum 31:313–319PubMedCrossRef
15.
16.
Walsh-Burke K, Marcusen C (1999) Self advocacy training for cancer survivors. Cancer Prac 7(6):297–301CrossRef
Metadata
Title
Measurement of self-advocacy in cancer patients and survivors
Author
Carol J. Hermansen-Kobulnicky
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 6/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0442-0

Other articles of this Issue 6/2008

Supportive Care in Cancer 6/2008 Go to the issue

Review Article

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib

Original Article

A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer

Short Communication

Communicating about illness: a family narrative

Review Article

A “TNM” classification system for cancer pain: The Edmonton Classification System for Cancer Pain (ECS-CP)

Editorial

Routine symptom assessment: good for practice and good for business

Original Article

Specialized palliative care services are associated with improved short- and long-term caregiver outcomes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits